Targeting Peptides Disrupt 14-3-3ε Binding for Squamous Cell Carcinoma

The patent introduces targeting peptides as intermediary molecules that specifically bind to 14-3-3 proteins in SCC cells, disrupting their interaction with CDC25A and inducing apoptosis. This peptide-mediated approach serves as a less invasive alternative to surgery, reducing patient trauma while maintaining therapeutic effectiveness through targeted molecular intervention

The patent replaces mechanical surgical intervention with a biochemical mechanism. Instead of physically removing tumors through surgery, the invention uses synthetic peptides to disrupt protein-protein interactions and trigger programmed cell death, substituting a mechanical system with a molecular-level biochemical system that achieves similar therapeutic goals with reduced harm

The targeting peptides exhibit local quality by specifically binding to 14-3-3 proteins within SCC cells through their designed amino acid sequences. This localized action at the molecular level allows selective disruption of cancer cell survival mechanisms without affecting normal cells, thereby controlling tumors while minimizing systemic side effects

The invention changes the therapeutic parameter from non-specific cytotoxicity to specific protein interaction disruption. By designing peptides with specific sequences that match 14-3-3 binding sites, the treatment shifts from broad-spectrum cancer therapy with severe side effects to targeted molecular intervention with improved safety profiles